Product Code: GVR-4-68039-065-9
Regulatory Affairs Market Growth & Trends
The global regulatory affairs market is expected to reach USD 27.0 billion by 2030, expanding at a CAGR of 8.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The factors expected to contribute to the growth of this market include changing regulatory requirements based on business activities and geographies, an increase in clinical trials & drug approvals along with accelerated regulatory approval, and technological advancement in regulatory software. Also, the evolution of personalized medicines, the increasing need for companies to focus on core business activities, and economic and competitive pressures are other factors that are contributing to the growth of the market.
The pharmaceutical and regulatory agencies joined forces to rapidly develop vaccines and medical products required to fight against the COVID-19 infection. The regulatory authorities take numerous precautions to ensure patient and personnel safety during a clinical trial, as well as data integrity and good laboratory practices are maintained. Growth in markets for biosimilars, orphan drugs, personalized medicines, companion diagnostics, and adaptive trial designs is projected to boost the demand for regulatory specialization in these areas. As companies venture into newer fields, the growing need to comply with regulations is boosting the demand for specialized service providers with expertise in regulatory affairs. Patent expiration of biologics, such as Simulect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services.
Several companies are actively involved in collaborations and new product development to gain leadership in the personalized medicine market, indicating a need for supportive regulatory affairs. For instance, in May 2020, Regeneron Pharmaceuticals, Inc. collaborated with Colorado Center for Personalized Medicine to design advancements in personalized medicine and human genetics.
Regulatory Affairs Market Report Highlights
- In terms of services, the regulatory writing & publishing segment dominated the market in 2022 with a revenue share of 36.6%. This is due to an increase in the outsourcing of these services by large- and mid-size medical device and biopharmaceutical companies
- Based on indications, the oncology segment accounted for the largest revenue share, 32.9%, in 2022. The segment share is attributed to the high prevalence of cancer, which is creating the need for safe and effective treatments
- Based on end-use, the pharmaceutical companies segment is anticipated to witness the highest growth rate of 9.0% from 2023 to 2030. A rise in the number of approved pharmaceutical products is the key factor responsible for the segment's growth
- Based on company size, the medium-sized companies segment dominated the global market in 2022 and accounted for the largest share of more than 47.0% of the overall revenue in the same year. An increasing number of medium-sized companies are penetrating the regulatory affairs market. Thereby, the segment held the lion's share in 2022 and across.
- Based on category, the biologics segment is anticipated to witness a stable growth rate of 8.0% during the analysis timeframe. The increasing pipeline of biologics to further boosts demand for its regulatory services, thus supporting segmental growth.
- Based on the product stage segment, the preclinical segment is anticipated to register the fastest growth of 9.4% across the analysis period. The high growth of the segment is majorly due to the increasing pipeline of small molecules and biosimilars across the globe.
- Based on the service provider segment, the outsourcing segment is anticipated to register the fastest growth of 10.3% across the analysis period. The high growth of the segment is majorly due to the increasing demand for cost-effective contract services.
- Asia Pacific is projected to witness the fastest growth rate of 9.3% during the forecast period on account of the improved regulatory landscape and growing venture activities by biopharmaceutical companies.
Table of Content
Chapter 1. Research Methodology And Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Segment Definitions
- 1.1.2. Services
- 1.1.3. Categories
- 1.1.4. Indication
- 1.2. Regional Scope
- 1.3. Estimates And Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. Parent Market Analysis
- 1.10. List Of Secondary Sources
- 1.11. List Of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Regulatory Affairs Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Changing Regulatory Landscape
- 3.2.1.2. Entry Of Companies Into The Global Market
- 3.2.1.3. Life Science Companies Focusing On Their Core Competencies
- 3.2.1.4. Economic And Competitive Pressures
- 3.2.1.5. Demand For The Faster Approval Process For Breakthrough Drugs And Devices
- 3.2.1.6. Growth In Emerging Areas Such As Personalized Medicine, Biosimilars, And Orphan Drugs
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Risk Associated With Data Security
- 3.2.2.2. Monitoring Issues And Lack Of Standardization
- 3.2.3. Industry Challenges
- 3.2.3.1. Managing Relationships
- 3.2.4. Major Deals and Strategic Alliances Analysis
- 3.2.4.1. Acquisition
- 3.2.4.2. Joint Venture
- 3.2.4.3. Expansions
- 3.2.4.4. Partnerships & Collaborations
- 3.2.4.5. Technology Advancements & Service Launches
- 3.2.5. Major Deals and Strategic Alliances Analysis of Biotech & Advanced Therapy Medicinal Products (ATMPs)
- 3.3. Regulatory Affairs Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat Of New Entrant
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTEL Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. COVID-19 Impact Analysis
- 3.3.4.1. COVID-19 Impact on Clinical Trials Services
- 3.3.4.2. COVID-19 Impact on Regulatory Services
- 3.3.4.3. COVID-19 Impact on Key Players
- 3.3.4.3.1. Medpace
- 3.3.4.3.2. Icon Plc
- 3.3.4.3.3. Charles River Laboratories
- 3.3.4.3.4. Labcorp Drug Development
- 3.3.4.4. Post COVID-19 Market Scenario
Chapter 4. Regulatory Affairs Market: Services Estimates & Trend Analysis
- 4.1. Regulatory Affairs Market, By Services: Segment Dashboard
- 4.2. Regulatory Affairs Market, By Services: Movement Analysis
- 4.3. Regulatory Affairs Market Estimates & Forecasts, By Services, 2018 - 2030
- 4.3.1. Regulatory Consulting
- 4.3.1.1. Regulatory Consulting Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 4.3.2. Legal Representation
- 4.3.2.1. Legal Representation Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 4.3.3. Regulatory Writing and Publishing
- 4.3.3.1. Regulatory Writing and Publishing Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 4.3.3.2. Writing
- 4.3.3.2.1. Writing Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 4.3.3.3. Publishing
- 4.3.3.3.1. Publishing Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 4.3.4. Product Registration and Clinical Trial Application
- 4.3.4.1. Product Registration and Clinical Trial Application Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 4.3.5. Other Regulatory Services
- 4.3.5.1. Other Regulatory Services Regulatory Affairs Market, 2018 to 2030 (USD Million)
Chapter 5. Regulatory Affairs Market: Categories Estimates & Trend Analysis
- 5.1. Regulatory Affairs Market, By Categories: Segment Dashboard
- 5.2. Regulatory Affairs Market, By Categories: Movement Analysis
- 5.3. Regulatory Affairs Market Estimates & Forecasts, By Categories, 2018 - 2030
- 5.3.1. Drugs
- 5.3.1.1. Drugs Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.1.2. Innovator
- 5.3.1.2.1. Innovator Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.1.2.2. Preclinical
- 5.3.1.2.2.1. Preclinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.1.2.3. Clinical
- 5.3.1.2.3.1. Clinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.1.2.4. PMA
- 5.3.1.2.4.1. PMA Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.1.3. Generics
- 5.3.1.3.1. Generics Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.1.3.2. Preclinical
- 5.3.1.3.2.1. Preclinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.1.3.3. Clinical
- 5.3.1.3.3.1. Clinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.1.3.4. PMA
- 5.3.1.3.4.1. PMA Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2. Biologics
- 5.3.2.1. Biologics Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.2. Biotech
- 5.3.2.2.1. Biotech Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.2.2. Preclinical
- 5.3.2.2.2.1. Preclinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.2.3. Clinical
- 5.3.2.2.3.1. Clinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.2.4. PMA
- 5.3.2.2.4.1. PMA Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.3. ATMP
- 5.3.2.3.1. ATMP Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.3.2. Preclinical
- 5.3.2.3.2.1. Preclinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.3.3. Clinical
- 5.3.2.3.3.1. Clinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.3.4. PMA
- 5.3.2.3.4.1. PMA Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.4. Biosimilars
- 5.3.2.4.1. Biosimilars Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.4.2. Preclinical
- 5.3.2.4.2.1. Preclinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.4.3. Clinical
- 5.3.2.4.3.1. Clinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.2.4.4. PMA
- 5.3.2.4.4.1. PMA Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3. Medical Devices
- 5.3.3.1. Medical Devices Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3.2. Diagnostics
- 5.3.3.2.1. Diagnostics Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3.2.2. Preclinical
- 5.3.3.2.2.1. Preclinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3.2.3. Clinical
- 5.3.3.2.3.1. Clinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3.2.4. PMA
- 5.3.3.2.4.1. PMA Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3.3. Therapeutics
- 5.3.3.3.1. Therapeutics Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3.3.2. Preclinical
- 5.3.3.3.2.1. Preclinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3.3.3. Clinical
- 5.3.3.3.3.1. Clinical Regulatory Affairs Market, 2018 to 2030 (USD Million)
- 5.3.3.3.4. PMA
- 5.3.3.3.4.1. PMA Regulatory Affairs Market, 2018 to 2030 (USD Million)
Chapter 6. Regulatory Affairs Market: Indication Estimates & Trend Analysis
- 6.1. Regulatory Affairs Market, By Indication: Segment Dashboard
- 6.2. Regulatory Affairs Market, By Indication: Movement Analysis
- 6.3. Regulatory Affairs Market Estimates & Forecasts, By Indication, 2018 - 2030
- 6.3.1. Oncology
- 6.3.1.1. Oncology Regulatory Affairs Market 2018 to 2030 (USD Million)
- 6.3.2. Neurology
- 6.3.2.1. Neurology Regulatory Affairs Market 2018 to 2030 (USD Million)
- 6.3.3. Cardiology
- 6.3.3.1. Cardiology Regulatory Affairs Market 2018 to 2030 (USD Million)
- 6.3.4. Hematology
- 6.3.4.1. Hematology Regulatory Affairs Market 2018 to 2030 (USD Million)
- 6.3.5. Immunology
- 6.3.5.1. Immunology Regulatory Affairs Market 2018 to 2030 (USD Million)
- 6.3.6. Others
- 6.3.6.1. Others Regulatory Affairs Market 2018 to 2030 (USD Million)
Chapter 7. Regulatory Affairs Market: Service Provider Segment Estimates & Trend Analysis
- 7.1. Regulatory Affairs Market, By Service Provider Segment: Segment Dashboard
- 7.2. Regulatory Affairs Market, By Service Provider Segment: Movement Analysis
- 7.3. Regulatory Affairs Market Estimates & Forecasts, By Service Provider Segment, 2018 - 2030
- 7.3.1. In-house
- 7.3.1.1. In-house Regulatory Affairs Market 2018 to 2030 (USD Million)
- 7.3.2. Outsourcing
- 7.3.2.1. Outsourcing Regulatory Affairs Market 2018 to 2030 (USD Million)
Chapter 8. Regulatory Affairs Market: Company Size Estimates & Trend Analysis
- 8.1. Regulatory Affairs Market, By Company Size: Segment Dashboard
- 8.2. Regulatory Affairs Market, By Company Size: Movement Analysis
- 8.3. Regulatory Affairs Market Estimates & Forecasts, By Company Size, 2018 - 2030
- 8.3.1. Small-sized
- 8.3.1.1. Small-sized Regulatory Affairs Market 2018 to 2030 (USD Million)
- 8.3.2. Medium-sized
- 8.3.2.1. Medium-sized Regulatory Affairs Market 2018 to 2030 (USD Million)
- 8.3.3. Large Companies
- 8.3.3.1. Large Companies Regulatory Affairs Market 2018 to 2030 (USD Million)
Chapter 9. Regulatory Affairs Market: Product Stage Estimates & Trend Analysis
- 9.1. Regulatory Affairs Market, By Product Stage: Segment Dashboard
- 9.2. Regulatory Affairs Market, By Product Stage: Movement Analysis
- 9.3. Regulatory Affairs Market Estimates & Forecasts, By Product Stage, 2018 - 2030
- 9.3.1. Preclinical
- 9.3.1.1. Preclinical Regulatory Affairs Market 2018 to 2030 (USD Million)
- 9.3.2. Clinical
- 9.3.2.1. Clinical Regulatory Affairs Market 2018 to 2030 (USD Million)
- 9.3.3. PMA
- 9.3.3.1. PMA Regulatory Affairs Market 2018 to 2030 (USD Million)
Chapter 10. Regulatory Affairs Market: End-use Estimates & Trend Analysis
- 10.1. Regulatory Affairs Market, By End-use: Segment Dashboard
- 10.2. Regulatory Affairs Market, By End-use: Movement Analysis
- 10.3. Regulatory Affairs Market Estimates & Forecasts, By End-use, 2018 - 2030
- 10.3.1. Medical Device Companies
- 10.3.1.1. Medical Device Companies Regulatory Affairs Market 2018 to 2030 (USD Million)
- 10.3.2. Pharmaceutical Companies
- 10.3.2.1. Pharmaceutical Companies Regulatory Affairs Market 2018 to 2030 (USD Million)
- 10.3.3. Biotechnology Companies
- 10.3.3.1. Biotechnology Companies Regulatory Affairs Market 2018 to 2030 (USD Million)
Chapter 11. Regulatory Affairs Market: Regional Estimates & Trend Analysis
- 11.1. Regional Market Share Analysis, 2022 & 2030
- 11.2. Regional Market Dashboard
- 11.3. Global Regional Market Snapshot
- 11.4. North America
- 11.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
- 11.4.2. U.S.
- 11.4.2.1. Key Country Dynamics
- 11.4.2.2. Competitive Scenario
- 11.4.2.3. Regulatory Framework
- 11.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
- 11.4.3. Canada
- 11.4.3.1. Key Country Dynamics
- 11.4.3.2. Competitive Scenario
- 11.4.3.3. Regulatory Framework
- 11.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
- 11.5. Europe
- 11.5.1. UK
- 11.5.1.1. Key Country Dynamics
- 11.5.1.2. Competitive Scenario
- 11.5.1.3. Regulatory Framework
- 11.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
- 11.5.2. Germany
- 11.5.2.1. Key Country Dynamics
- 11.5.2.2. Competitive Scenario
- 11.5.2.3. Regulatory Framework
- 11.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
- 11.5.3. France
- 11.5.3.1. Key Country Dynamics
- 11.5.3.2. Competitive Scenario
- 11.5.3.3. Regulatory Framework
- 11.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
- 11.5.4. Italy
- 11.5.4.1. Key Country Dynamics
- 11.5.4.2. Competitive Scenario
- 11.5.4.3. Regulatory Framework
- 11.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
- 11.5.5. Spain
- 11.5.5.1. Key Country Dynamics
- 11.5.5.2. Competitive Scenario
- 11.5.5.3. Regulatory Framework
- 11.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
- 11.5.6. Russia
- 11.5.6.1. Key Country Dynamics
- 11.5.6.2. Competitive Scenario
- 11.5.6.3. Regulatory Framework
- 11.5.6.4. Russia Market Estimates and Forecasts, 2018 - 2030
- 11.5.7. Turkey
- 11.5.7.1. Key Country Dynamics
- 11.5.7.2. Competitive Scenario
- 11.5.7.3. Regulatory Framework
- 11.5.7.4. Turkey Market Estimates and Forecasts, 2018 - 2030
- 11.5.8. Netherlands
- 11.5.8.1. Key Country Dynamics
- 11.5.8.2. Competitive Scenario
- 11.5.8.3. Regulatory Framework
- 11.5.8.4. Netherlands Market Estimates and Forecasts, 2018 - 2030
- 11.5.9. Switzerland
- 11.5.9.1. Key Country Dynamics
- 11.5.9.2. Competitive Scenario
- 11.5.9.3. Regulatory Framework
- 11.5.9.4. Switzerland Market Estimates and Forecasts, 2018 - 2030
- 11.5.10. Sweden
- 11.5.10.1. Key Country Dynamics
- 11.5.10.2. Competitive Scenario
- 11.5.10.3. Regulatory Framework
- 11.5.10.4. Sweden Market Estimates and Forecasts, 2018 - 2030
- 11.6. Asia Pacific
- 11.6.1. Japan
- 11.6.1.1. Key Country Dynamics
- 11.6.1.2. Competitive Scenario
- 11.6.1.3. Regulatory Framework
- 11.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
- 11.6.2. India
- 11.6.2.1. Key Country Dynamics
- 11.6.2.2. Competitive Scenario
- 11.6.2.3. Regulatory Framework
- 11.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
- 11.6.3. China
- 11.6.3.1. Key Country Dynamics
- 11.6.3.2. Competitive Scenario
- 11.6.3.3. Regulatory Framework
- 11.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
- 11.6.4. South Korea
- 11.6.4.1. Key Country Dynamics
- 11.6.4.2. Competitive Scenario
- 11.6.4.3. Regulatory Framework
- 11.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
- 11.6.5. Australia
- 11.6.5.1. Key Country Dynamics
- 11.6.5.2. Competitive Scenario
- 11.6.5.3. Regulatory Framework
- 11.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
- 11.6.6. Thailand
- 11.6.6.1. Key Country Dynamics
- 11.6.6.2. Competitive Scenario
- 11.6.6.3. Regulatory Framework
- 11.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
- 11.6.7. Indonesia
- 11.6.7.1. Key Country Dynamics
- 11.6.7.2. Competitive Scenario
- 11.6.7.3. Regulatory Framework
- 11.6.7.4. Indonesia Market Estimates and Forecasts, 2018 - 2030
- 11.6.8. Malaysia
- 11.6.8.1. Key Country Dynamics
- 11.6.8.2. Competitive Scenario
- 11.6.8.3. Regulatory Framework
- 11.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030
- 11.6.9. Singapore
- 11.6.9.1. Key Country Dynamics
- 11.6.9.2. Competitive Scenario
- 11.6.9.3. Regulatory Framework
- 11.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030
- 11.6.10. Taiwan
- 11.6.10.1. Key Country Dynamics
- 11.6.10.2. Competitive Scenario
- 11.6.10.3. Regulatory Framework
- 11.6.10.4. Taiwan Market Estimates and Forecasts, 2018 - 2030
- 11.7. Latin America
- 11.7.1. Brazil
- 11.7.1.1. Key Country Dynamics
- 11.7.1.2. Competitive Scenario
- 11.7.1.3. Regulatory Framework
- 11.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
- 11.7.2. Mexico
- 11.7.2.1. Key Country Dynamics
- 11.7.2.2. Competitive Scenario
- 11.7.2.3. Regulatory Framework
- 11.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
- 11.7.3. Argentina
- 11.7.3.1. Key Country Dynamics
- 11.7.3.2. Competitive Scenario
- 11.7.3.3. Regulatory Framework
- 11.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
- 11.7.4. Colombia
- 11.7.4.1. Key Country Dynamics
- 11.7.4.2. Competitive Scenario
- 11.7.4.3. Regulatory Framework
- 11.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
- 11.7.5. Chile
- 11.7.5.1. Key Country Dynamics
- 11.7.5.2. Competitive Scenario
- 11.7.5.3. Regulatory Framework
- 11.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030
- 11.8. Middle East & Africa
- 11.8.1. South Africa
- 11.8.1.1. Key Country Dynamics
- 11.8.1.2. Competitive Scenario
- 11.8.1.3. Regulatory Framework
- 11.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
- 11.8.2. Saudi Arabia
- 11.8.2.1. Key Country Dynamics
- 11.8.2.2. Competitive Scenario
- 11.8.2.3. Regulatory Framework
- 11.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
- 11.8.3. UAE
- 11.8.3.1. Key Country Dynamics
- 11.8.3.2. Competitive Scenario
- 11.8.3.3. Regulatory Framework
- 11.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
- 11.8.4. Egypt
- 11.8.4.1. Key Country Dynamics
- 11.8.4.2. Competitive Scenario
- 11.8.4.3. Regulatory Framework
- 11.8.4.4. Egypt Market Estimates and Forecasts, 2018 - 2030
- 11.8.5. Israel
- 11.8.5.1. Key Country Dynamics
- 11.8.5.2. Competitive Scenario
- 11.8.5.3. Regulatory Framework
- 11.8.5.4. Israel Market Estimates and Forecasts, 2018 - 2030
Chapter 12. Competitive Landscape
- 12.1. Market Participant Categorization
- 12.1.1. Innovators
- 12.1.2. Market Leaders
- 12.1.3. Emerging Players
- 12.1.4. Company Market Share Analysis, 2022
- 12.2. Company Profiles
- 12.2.1. Accell Clinical Research, LLC
- 12.2.1.1. Company Overview
- 12.2.1.2. Financial Performance
- 12.2.1.3. Service Benchmarking
- 12.2.1.4. Strategic Initiatives
- 12.2.2. Genpact
- 12.2.2.1. Company Overview
- 12.2.2.2. Financial Performance
- 12.2.2.3. Service Benchmarking
- 12.2.2.4. Strategic Initiatives
- 12.2.3. Criterium, Inc.
- 12.2.3.1. Company Overview
- 12.2.3.2. Financial Performance
- 12.2.3.3. Service Benchmarking
- 12.2.3.4. Strategic Initiatives
- 12.2.4. ICON plc
- 12.2.4.1. Company Overview
- 12.2.4.2. Financial Performance
- 12.2.4.3. Service Benchmarking
- 12.2.4.4. Strategic Initiatives
- 12.2.5. Promedica International
- 12.2.5.1. Company Overview
- 12.2.5.2. Financial Performance
- 12.2.5.3. Service Benchmarking
- 12.2.5.4. Strategic Initiatives
- 12.2.6. WuXi AppTec
- 12.2.6.1. Company Overview
- 12.2.6.2. Financial Performance
- 12.2.6.3. Service Benchmarking
- 12.2.6.4. Strategic Initiatives
- 12.2.7. Medpace
- 12.2.7.1. Company Overview
- 12.2.7.2. Financial Performance
- 12.2.7.3. Service Benchmarking
- 12.2.7.4. Strategic Initiatives
- 12.2.8. Charles River Laboratories
- 12.2.8.1. Company Overview
- 12.2.8.2. Financial Performance
- 12.2.8.3. Service Benchmarking
- 12.2.8.4. Strategic Initiatives
- 12.2.9. Labcorp Drug Development
- 12.2.9.1. Company Overview
- 12.2.9.2. Financial Performance
- 12.2.9.3. Service Benchmarking
- 12.2.9.4. Strategic Initiatives
- 12.2.10. Parexel International Corporation
- 12.2.10.1. Company Overview
- 12.2.10.2. Financial Performance
- 12.2.10.3. Service Benchmarking
- 12.2.10.4. Strategic Initiatives
- 12.2.11. Freyr
- 12.2.11.1. Company Overview
- 12.2.11.2. Financial Performance
- 12.2.11.3. Service Benchmarking
- 12.2.11.4. Strategic Initiatives
- 12.2.12. Pharmalex GmbH
- 12.2.12.1. Company Overview
- 12.2.12.2. Financial Performance
- 12.2.12.3. Service Benchmarking
- 12.2.12.4. Strategic Initiatives
- 12.2.13. NDA Group AB
- 12.2.13.1. Company Overview
- 12.2.13.2. Financial Performance
- 12.2.13.3. Service Benchmarking
- 12.2.13.4. Strategic Initiatives
- 12.2.14. Pharmexon
- 12.2.14.1. Company Overview
- 12.2.14.2. Financial Performance
- 12.2.14.3. Service Benchmarking
- 12.2.14.4. Strategic Initiatives
- 12.2.15. Qvigilance
- 12.2.15.1. Company Overview
- 12.2.15.2. Financial Performance
- 12.2.15.3. Service Benchmarking
- 12.2.15.4. Strategic Initiatives
- 12.2.16. BlueReg
- 12.2.16.1. Company Overview
- 12.2.16.2. Financial Performance
- 12.2.16.3. Service Benchmarking
- 12.2.16.4. Strategic Initiatives
- 12.2.17. Cambridge Regulatory Services
- 12.2.17.1. Company Overview
- 12.2.17.2. Financial Performance
- 12.2.17.3. Service Benchmarking
- 12.2.17.4. Strategic Initiatives
- 12.2.18. VCLS
- 12.2.18.1. Company Overview
- 12.2.18.2. Financial Performance
- 12.2.18.3. Service Benchmarking
- 12.2.18.4. Strategic Initiatives
Chapter 13. Kol Commentary/Key Recommendations